Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today ...

To combat long-overlooked fungal pathogens, researchers and regulators must embrace innovative science and policy.

Crop spraying in the United States could make a £250 million antifungal drug ineffective before it even reaches the market, ...

While about a dozen classes of antibiotics are available to treat bacterial infections, there are only three main classes of antifungals, she said. "We also have to be concerned about how we are ...

Genomic changes in the infectious yeast Candida tropicalis may play a role in its resistance to antifungals, according to a study published in PLOS Biology. The work, led by Guanghua Huang at ...

It is primarily treated with antifungal medicine, not antibiotics. In fact, antibiotics may increase the risk by “killing off normal protective bacteria in the vagina, leading to an overgrowth of ...

Health officials are raising the alarm over a deadly fungus described as similar to 'having cancer' that is surging in US hospitals. Candida Auris, a type of yeast resistant to most treatments ...

The low return on investment means many of the biggest biopharmas have given up working on new antifungals or antibiotics in recent years—although GSK in particular has continued to sign deals ...

Light therapy effectively targets the fungus directly while encouraging healthier nail regrowth, unlike conventional antifungal treatments that may take months to show results. The Okita Nail ...

Or sign-in if you have an account. More information is coming out about how quickly cases of Candida auris — a deadly fungus that can resist antifungal drugs — are increasing after it was ...

auris, as it not only is highly resistant to multiple antifungal drugs but also can withstand common hospital disinfectants. “CDC has deemed C. auris as an urgent AR [antimicrobial resistance ...

The MIC values of the azole antifungals and 5-FC were defined as the minimum drug concentration at which visual growth was determined to be 50% relative to that of the growth control, known as MIC 50.